These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12787848)

  • 1. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
    D'Amico G; Cedro C; Muscatello MR; Pandolfo G; Di Rosa AE; Zoccali R; La Torre D; D'Arrigo C; Spina E
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):619-23. PubMed ID: 12787848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
    Francobandiera G
    Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.
    Bizouard P; Vandel S; Kantelip JP
    Therapie; 2001; 56(4):443-5. PubMed ID: 11677871
    [No Abstract]   [Full Text] [Related]  

  • 11. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
    Poyurovsky M; Dorfman-Etrog P; Hermesh H; Munitz H; Tollefson GD; Weizman A
    Int Clin Psychopharmacol; 2000 May; 15(3):169-73. PubMed ID: 10870875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?
    Maina G; Albert U; Ziero S; Bogetto F
    Int Clin Psychopharmacol; 2003 Jan; 18(1):23-8. PubMed ID: 12490771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
    Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
    J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
    [No Abstract]   [Full Text] [Related]  

  • 15. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
    Shapira NA; Ward HE; Mandoki M; Murphy TK; Yang MC; Blier P; Goodman WK
    Biol Psychiatry; 2004 Mar; 55(5):553-5. PubMed ID: 15023585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
    Ramasubbu R; Ravindran A; Lapierre Y
    Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.
    Diniz JB; Shavitt RG; Pereira CA; Hounie AG; Pimentel I; Koran LM; Dainesi SM; Miguel EC
    J Psychopharmacol; 2010 Mar; 24(3):297-307. PubMed ID: 19164490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.
    Denys D; van Megen HJ; van der Wee N; Westenberg HG
    J Clin Psychiatry; 2004 Jan; 65(1):37-43. PubMed ID: 14744166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.
    Atmaca M; Kuloglu M; Tezcan E; Gecici O
    Int Clin Psychopharmacol; 2002 May; 17(3):115-9. PubMed ID: 11981352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.